Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.71 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MMP12 | P39900 | 5/20 | 0.45 |
| ▸ | MMP13 | P45452 | 5/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | MMP14 | P50281 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26138089 | 0.97 | SLC22A6 (0.75) | SLC22A6GABRR1LMNAGPR84MAPT | |
| SCHEMBL9767479 | 0.89 | SLC22A6 (0.57) | SLC22A6GABRR1LMNAGPR84MAPT | |
| SCHEMBL14235649 | 0.88 | SLC22A6 (0.63) | SLC22A6GABRR1LMNAGPR84MAPT | |
| SCHEMBL14873018 | 0.88 | SLC22A6 (0.63) | SLC22A6GABRR1LMNAGPR84MAPT | |
| SCHEMBL27623054 | 0.87 | SLC22A6 (0.55) | SLC22A6GABRR1LMNAGPR84MAPT | |
| SCHEMBL9078197 | 0.87 | GABRR1 (0.58) | SLC22A6GABRR1LMNAGPR84MAPT | |
| SCHEMBL966415 | 0.85 | GPR84 (0.74) | SLC22A6GABRR1LMNAGPR84MAPT | |
| SCHEMBL28922166 | 0.85 | GPR84 (0.67) | SLC22A6GABRR1LMNAGPR84MAPT | |
| SCHEMBL665350 | 0.84 | SLC22A6 (0.57) | SLC22A6GABRR1LMNAGPR84MAPT | |
| SCHEMBL16600523 | 0.84 | SLC22A6 (0.57) | SLC22A6GABRR1LMNAGPR84MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111936667-A | Method for producing laminate | 大金工业株式会社 | 2020-11-13 | — | — | CN | disclosed |
| US-7834126-B2 | Amide-containing polymers for rheology control | BYK-CHEMIE GMBH (DE) | 2010-11-16 | — | — | US | disclosed |
| US-7799890-B2 | Amide-containing polymers for rheology control | BYK-CHEMIE GMBH (DE) | 2010-09-21 | — | — | US | disclosed |
| US-7655815-B2 | Biuret compounds for rheology control | BYK-CHEMIE GMBH (DE) | 2010-02-02 | — | — | US | disclosed |
| US-7652166-B2 | Biuret- and uretidone- containing ompounds having urethane or carbamate groups; chemical intermediates; polyurethanes; polyureas; polyetherurethane copolymers;flow control agents of epoxy resins and polyepoxides; thixotropic agents; paints;plasticols; coatings; radiation transparent coatings | BYK-CHEMIE GMBH (DE) | 2010-01-26 | — | — | US | disclosed |
| US-20080132671-A1 | AMIDE-CONTAINING POLYMERS FOR RHEOLOGY CONTROL | BYK-CHEMIE GMBH | 2008-06-05 | — | — | US | disclosed |
| US-20070225451-A1 | uretidone-containing compound from the reaction of a diisocyanate and alcohol; biuret derivative as end group for polyoxyethylene glycol;used in thixotroping coating systems for creep resistance and nonsettling properties; improved effect profile and improved reproducibility of thixotroping | BYK-CHEMIE GMBH (DE) | 2007-09-27 | — | — | US | disclosed |
| US-20070088148-A1 | Amide-containing polymers for rheology control | BYK-CHEMIE GMBH (DE) | 2007-04-19 | — | — | US | disclosed |
| US-20060276675-A1 | Biuret compounds, their preparation and use, and intermediates in their preparation | BYK-CHEMIE GMBH (DE) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276675-A1 | Biuret compounds, their preparation and use, and intermediates in their preparation | UTS2R, CCNT2, CCNT1 | SLC22A6 2796/4885GABRR1 1353/4885LMNA 947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.